基于SIRT1治疗胆汁淤积性肝损伤的作用机制及药物研究进展  

Research progress in mechanisms of action and drugs in SIRT1-based treatment of cholestatic liver injury

作　　者：王长玲[1] 江振洲[1,3] 张陆勇 王涛[1] WANG Chang⁃ling;JIANG Zhen⁃zhou;ZHANG Lu⁃yong;WANG Tao(Jiangsu Key Laboratory of Drug Screening,China Pharmaceutical University,Nanjing 210009,China;Center for Drug Research and Development,Guangdong Pharmaceutical University,Guangzhou 510006,China;Jiangsu Center for Phar⁃macodynamics Research and Evaluation,China Pharmaceutical University,Nanjing 210009,China)

机构地区：[1]中国药科大学江苏省新药筛选重点实验室,南京210009 [2]广东药科大学新药研发中心,广州510006 [3]中国药科大学江苏省药效研究与评价服务中心,南京210009

出　　处：《军事医学》2020年第5期390-395,共6页Military Medical Sciences

基　　金：公益性行业科研专项(201507004-002);国家“重大新药创制专项”(2015ZX09501004-002-004)

摘　　要：胆汁淤积性肝损伤是胆汁酸在肝内及体内蓄积而诱发的肝脏病变,其发病机制可能与肝细胞胆汁酸稳态、炎症、氧化应激、线粒体功能、纤维化、肝再生有关,目前尚无有效治疗药物。沉默信息调节因子2相关酶1(SIRT1)是一种NAD+依赖性去乙酰化酶,在胆汁淤积性肝损伤的治疗中发挥着重要作用,有望成为胆汁淤积肝损伤治疗的新靶点。该文综述了SIRT1在胆汁淤积中的作用机制及以SIRT1为靶点治疗胆汁淤积性肝损伤的相关药物研究进展。Cholestasis liver injury is a disease which is caused by accumulation of bile acids in the liver and in vivo.Its pathogenesis may be related to bile acid homeostasis,inflammation,oxidative stress,mitochondrial function,fibrosis and liver regeneration in the hepatocyte,but there is no effective drug currently available.Silent information regulator factor 2-related enzyme 1(SIRT1)is an NAD+dependent deacetylase,which plays an important role in the treatment of cholestasis liver injury and is expected to become a new target.This review aims to outlines the mechanisms of SIRT1 in cholestasis liver injury and the research progress in related drugs.

关 键 词：沉默信息调节因子2相关酶1 胆汁淤积肝损伤 作用机制 药物 

分 类 号：R575[医药卫生—消化系统]